



CASE D0273 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304413589US  
Express Mail Label Number

December 4, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1656

HUANG ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING  
ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR  
MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN  
TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: December 4, 2006

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



CASE D0273 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304413589US  
Express Mail Label Number

December 4, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1656

HUANG ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING  
ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR  
MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN  
TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the  
references cited on the attached form(s) PTO-1449.

These references were cited in an Invitation to Pay Additional Fees in a corresponding PCT  
International application. Copies of these references and the search report are enclosed herewith.

12/06/2006 H0000001 193880 10648593

01 FC:1806 180.00 DA


Statement Under 37 C.F.R. § 1.704(d)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application no more than 30 days prior to the filing of this Statement.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: December 4, 2006

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
D0273 NP  
APPLICATION NO.  
10/648,593  
APPLICANT  
HUANG ET AL.  
FILING DATE  
AUGUST 26, 2003Group  
1656

## INFORMATION DISCLOSURE CITATION



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2004/0106132 A1	6/3/04	Huang, et al.			
	AB	2006/0019284 A1	1/26/06	Huang, et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO2004/020583A2	3/11/04	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO2006/005035A2	1/12/06	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO03/062395A2	7/31/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO00/62778	10/26/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO2004/085388A2	10/7/04	PCT			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.